On Thursday, October 25, Technology Transfer and Business Development (TTBD) hosted the 2012 Technology Innovation Awards to recognize OHSU researchers who had technologies licensed or optioned in the last fiscal year as well as those who brought in top dollars from industry to support their research. The ceremony drew a large crowd to the Casey Eye Institute Macdonald Auditorium and featured keynote speaker Kenton Gregory, M.D., FACC, head of OHSU’s new Center for Regenerative Medicine.
We’d like to congratulate all of the researchers who were recognized at this year’s Innovation Awards ceremony, including:
Business Partnership Achievement Award: Jeffrey Kaye, M.D.
Dr. Kaye is director of the Layton Aging & Alzheimer’s Disease Center at the Department of Neurology and co-director of of the Oregon Center for Aging & Technology (ORCATECH). For the last two years, Dr. Kaye has worked very closely with the Business Development group within TTBD to champion ORCATECH and its capabilities to pharma, biotech companies, and OHSU leadership. Due to this joint effort, ORCATECH is now receiving attention from pharma companies who have expressed willingness to partner with OTCATECH for clinical trials and research programs.
New Inventor of the Year Award: David Huang, M.D., Ph.D.
In 1991, Dr. Huang co-invented Optical Coherence Tomography (OCT), and imaging tool that has revolutionized the field of ophthalmology. In recognition of this contribution, Dr. Huang and his colleagues won the 2012 António Champalimaud Vision Award this year (considered the Nobel Prize for vision). TTBD received four invention disclosures during Dr. Huang’s first year at OHSU, three of which are subject to patent protection. One such technology is an OCT imaging software that improves the signal-to-noise ratio of flow detection and enables detailed vascular images. TTBD is currently engaged in negotiations to license this technology to an OCT company.
Technology Transfer Achievement Award: Charles Keller, M.D.
Dr. Keller begins and ends his day corresponding with families that look to him for hope and for an explanation of their child’s rare form of cancer. The Keller Lab studies the driving mechanisms and therapeutic targets in childhood muscle and brain cancers; an area of unmet medical need easily overlooked by drug development companies. Since Dr. Keller’s tenure began at OHSU, he has become a prominent leader in the field, exemplified by his inauguration into the National Cancer Institute-supported Pediatric Preclinical Testing Program and the Children’s Oncology Group. Dr. Keller believes in collaborative research environments and is continually building relationships worldwide.
For a full list of Technology Innovation Award recipients, view the 2012 Technology Innovation Awards program. Learn more about OHSU’s Technology Transfer and Business Development office by checking out this recent article from the Portland Business Journal (subscription required – summary available here).